Sam Chun Dang Pharm

Sam Chun Dang Pharm Co., Ltd.
Native name
삼천당제약
TypePublic
KRX: 000250
IndustryPharmaceuticals
FoundedDecember 29, 1943; 82 years ago (1943-12-29)
HeadquartersSeocho-gu, Seoul, South Korea
Key people
Yoon Dae-in (Chairman)
Chun In-seok (Chief Executive Officer)
ProductsOphthalmic drugs, cardiovascular drugs, antibiotics, biosimilars, GLP-1 generics
Websitewww.scd.co.kr

Sam Chun Dang Pharm Co., Ltd. (Korean: 삼천당제약; Hanja: 三千堂製藥; RR: Samcheondang jeyak), commonly abbreviated as SCD, is a South Korean pharmaceutical company engaged in the development, manufacturing, and sale of prescription medicines.[1] Founded in 1943, the company is headquartered in Seocho-gu, Seoul, with manufacturing operations at the Hyannam Pharmaceutical Industrial Complex in Hwaseong, Gyeonggi Province. SCD is listed on the Korea Exchange (KRX: 000250).[2]

The company is best known for its ophthalmic products, which accounts for approximately half of its total revenues, and has attracted attention for its development of an aflibercept biosimilar (SCD411) and an oral semaglutide generic.[3]

History

Sam Chun Dang Pharm was established on December 29, 1943, to manufacture and sell pharmaceutical products. The company is widely recognized as the first Korean pharmaceutical company to manufacture eye drops.[4]

In 1985, SCD constructed a KGMP-certified factory within the Hyannam Pharmaceutical Industrial Complex in Hwaseong, Gyeonggi Province.[5]

In 2013, SCD acquired Optus Pharmaceuticals [ko], at the time the leading domestic manufacturer of single-use ophthalmic eye drops.

SCD received the European Union Good Manufacturing Practice certification from the UK MHRA in March 2015, and a further EU GMP certificate from Germany's BGV in April 2018, allowing the company to expand into international markets.[6][7]

Products

SCD411: Aflibercept Biosimilar

SCD411 is a biosimilar referencing Regeneron and Bayer's Eylea, an anti-VEGF therapy indicated for neovascular age-related macular degeneration (wet AMD) and other retinal diseases. The drug completed global Phase 3 clinical trials in 2022 across 14 countries, involving 576 patients at 132 hospitals.[8]

SCD411 received regulatory approvals in Canada (June 2025), Europe (August 2025), South Korea, and Japan (both September 2025), in both vial and pre-filled syringe formats.[9][10]

Oral GLP-1 Semaglutide Generic

SCD has been developing an oral generic version of semaglutide, the active ingredient in Novo Nordisk's Wegovy and Ozempic.[11]

In January 2026, SCD signed a partnership agreement with Daiichi Sankyo Espha, a subsidiary of Japan's Daiichi Sankyo, for the exclusive sale of oral semaglutide generics in Japan.[12][13][circular reference]

Some industry observers and analysts have questioned the company's public statements regarding this product. A commentary published by the Korea Biomedical Review in July 2025 noted that SCD's claims of a potential 2026 market launch for its oral semaglutide generic appeared to overstate the company's regulatory position, given that secondary patents on semaglutide formulations are widely expected to remain in force until at least 2031 in most major markets.[1]

See also

References

  1. ^ a b "[Reporter's Notebook] Sam Chun Dang Pharm's misleading hype over oral GLP-1 trial data". Korea Biomedical Review. July 25, 2025. Retrieved February 20, 2026.
  2. ^ 메디컬투데이 (June 18, 2025). "삼천당제약, 1분기 매출 500억 돌파...안과용제 성장 견인". mdtoday.co.kr (in Korean). Retrieved February 21, 2026.
  3. ^ Kang, John. "Promising New Weight-Loss Pill From South Korea's Sam Chun Dang Pharm Mints Country's Newest Billionaire". Forbes. Archived from the original on February 18, 2026. Retrieved February 21, 2026.
  4. ^ "삼천당제약 기업현황". 기업모니터. Retrieved February 20, 2026.
  5. ^ "R&D News - Samchundang Pharma Signs 20-Year Exclusive License Agreement with Fresenius Kabi for Aflibercept Biosimilar in the U.S. and Latin America". BQURA. Retrieved February 21, 2026.
  6. ^ "A Brief Company Profile of SamChunDang Pharm" (PDF). SCD. Retrieved February 20, 2026.
  7. ^ Yeom, Hyun-a (July 28, 2025). "Korean biosimilar firms pursue European market as Eylea patent nears expiration". CHOSUNBIZ. Retrieved February 21, 2026.
  8. ^ Kim, Jae-sun (December 23, 2024). "Sam Chun Dang Pharm partners with Fresenius Kabi for Eylea biosimilar commercialization in US, Latin America". Korea Biomedical Review. Retrieved February 20, 2026.
  9. ^ "Sam Chun Dang wins Korea and Japan OKs for Eylea biosimilar". Korea Biomedical Review. September 22, 2025. Retrieved February 20, 2026.
  10. ^ "Sam Chun Dang's Biosimilar Aflibercept Approved in Japan and Korea". Pearce IP. September 30, 2025. Retrieved February 20, 2026.
  11. ^ "Sam Chun Dang Pharm begins bioequivalence study for oral semaglutide". Korea Biomedical Review. January 22, 2025. Retrieved February 20, 2026.
  12. ^ "Wegovy Generics Surge as Semaglutide Patents Expire". BusinessKorea. Retrieved February 20, 2026.
  13. ^ "삼천당제약". 위키백과. Retrieved February 20, 2026.

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.